Comparing two surgical techniques for treating cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness and safety of laparoscopic radical hysterectomy incorporating modified tumor-free techniques (LRH-MTF) compared to traditional abdominal radical hysterectomy (ARH) for patients with FIGO stage IB2 cervical cancer. Participants will be randomly assigned to undergo either LRH-MTF or ARH and will be monitored for disease-free survival rates and complications over a period of 4.5 years post-operation. The study also includes follow-up assessments and quality-of-life questionnaires to gather comprehensive data on patient outcomes.

Why it matters

Who can join: the full rules

1. Inclusion Criteria:

   1.1 Females aged 18 to 65 years old. 1.2 Histologically confirmed primary cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.

   1.3 FIGO 2018 stage IB2. 1.4 The maximum diameter of the cervical lesion measured by MRI is \>2 cm and ≤4 cm. For those with MRI contraindications, PET/CT, CT, or ultrasound can be used as alternatives.

   1.5 Scheduled to receive type C (Q - M classification) radical hysterectomy. 1.6 Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

   1.7 Willing to participate in this trial and sign the informed consent form. 1.8 Able to cooperate and complete follow - up and relevant examinations. 1.9 For pre - menopausal women, a negative pregnancy test within 30 days before surgery.

   1.10 Laboratory test indicators of vital organs meet the standards
2. Exclusion Criteria:

2.1 Special pathological types (gastric - type adenocarcinoma, neuroendocrine carcinoma, clear cell carcinoma, carcinosarcoma, etc.).

2.2 Imaging examinations suggest pelvic or para - aortic lymph node metastasis (MRI or CT shows a short - axis diameter of ≥1.5 cm, or SUV ≥2.5), or histopathology indicates lymph node metastasis.

2.3 History of pelvic and abdominal radiotherapy. 2.4 History of neoadjuvant chemotherapy. 2.5 Uterus larger than that at 10 weeks of pregnancy. 2.6 Contraindications for surgery and anesthesia (such as severe medical comorbidities).

2.7 Patients who cannot tolerate the Trendelenburg position. 2.8 Patients who cannot cooperate with treatment and follow - up. 2.9 Pregnant patients. 2.10 History of other malignancies, except for those who have been cancer - free for more than 3 years with no current evidence of tumor recurrence.

Where it's running

• Sun Yat-sen Memorial Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting
• Cangzhou Central Hospital
  Cangzhou, Hebei, China Recruiting
• The Fourth Hospital of Hebei Medical University
  Shijiazhuang, Hebei, China Recruiting
• Hunan Provincial Maternal and Child Health Care Hospital
  Changsha, Hunan, China Recruiting
• The Second Hospital of Jilin University
  Changchun, Jilin, China Recruiting
• Renji Hospital Affiliated to The Shanghai Jiao Tong University Medical School
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Yuan Li, professor
• Email: liyuan10833@pumch.cn
• Phone: +8617810376318

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Growing cervical cancer organoids from diagnostic biopsy samples

  We will try to grow tiny, patient-specific tumor organoids from biopsy tissue collected during diagnostic biopsy in adults with suspected stage IB2–IIIA cervical cancer so labs can test treatments on them.

  Recruiting Regina Elena Cancer Institute · Roma, RM · NCT07248878

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Glycogen Storage Disease and Brain Function in People Like You

  This study tests whether people with glycogen storage disease perform differently on cognitive tests and show different brain imaging features compared with healthy peers.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07908212

• FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy

  This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07878338

• Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer

  This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07854600

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.